167838-46-2

Upstream product

• 167837-47-0 N-(3-((tert-butyldiphenylsilyloxy)methyl)-2,4-dichlorophenyl)-2-(1,3-dioxoisoindolin-2-yl)-N-methylacetamide 
• 167837-46-9 N-(3-((tert-butyldiphenylsilyloxy)methyl)-2,4-dichlorophenyl)-2-(1,3-dioxoisoindol-in-2-yl)-acetamide 
• 167834-64-2 8-[2,6-dichloro-3-[N-(phthalimidoacetyl)-N-methylamino]benzyloxy]-2-methylquinoline 
• 167837-49-2 2,6-dichloro-1-methylsulfonyloxymethyl-3-[N-methyl-N-(phthalimidoacetyl)amino]benzene 
• 167837-44-7 tert-butyl(2,6-dichloro-3-nitrobenzyloxy)diphenylsilane 
• 167837-48-1 N-(2,4-dichloro-3-(hydroxymethyl)phenyl)-2-(1,3-dioxoisoindolin-2-yl)-N-methylacetamide 
• 167837-45-8 3-amino-1-(tert-butyldiphenylsilyloxymethyl)-2,6-dichlorobenzene 
• 160647-01-8 2,6-Dichloro-3-nitrobenzyl alcohol 
• 826-81-3 2-methyl-8-quinolinol 
• 167834-66-4 8-[3-(N-glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-2-methylquinoline 
• 167837-43-6 (2E)-3-(6-amino-3-pyridinyl)-2-propenoic acid 

Relevant academic research and scientific papers

Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists

This invention relates to a compound of the formula: STR1 wherein Z is a group of the formula: STR2 in which X1 is N or C--R1, X2 is N or C--R9, X3 is N or C--R2, R1 is lower alk

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a]pyridine moiety

Recently we reported on overcoming the species difference of our first orally active non-peptide bradykinin (BK) B2 receptor antagonists, incorporating an 8-[[3-(N-acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]- 3-halo-2-methylimidazo[1,2-α]

BRADYKININ ANTAGONIST QUINOLINES

This invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof. More particularly, this invention relates to new heterocyclic compounds and salts thereof which display bradykinin antagonist activity, to processes for preparing these compounds, to a pharmaceutical composition comprising these compounds, and to methods of using same in the prevention and/or the treatment of bradykinin-or bradykinin analogue-mediated diseases such as allergy, inflammation, autoimmune disease, shock, pain, or the like, in human beings or in animals.